Management of Pulmonary Fibrosis from COVID-19 Pneumonia with Nintedanib
Article Sidebar
Main Article Content
Abstract
OBJECTIVES: To propose the benefit of antifibrotic agent, nintedanib, in the treatment of lung fibrosis from SARS-CoV-2 Coronavirus 2019 (COVID-19) pneumonia, based on experience at Bangkok Hospital Headquarters, Bangkok, Thailand.
MATERIALS AND METHODS: Data from patients who developed lung fibrosis post COVID-19 pneumonia during 2020-2022 at our institute, all developed severe pneumonia, was analyzed, including clinical signs and symptoms, imaging findings, O2 saturation: at room air and during 6 minutes’ walk, and response to treatment.
RESULTS: Among 10 patients with COVID-19 lung fibrosis who received steroids, remdesivir and nintedanib; 2 patients (20%) expired, 7 patients (70%) were back to normal within 3 months, and 1 patient (10%) was able to walk with oxygen 2 liter per minute (LPM) after 7 months.
CONCLUSION: An antifibrotic agent, such as nintedanib, could improve lung fibrosis from COVID-19 pneumonia.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
This article is published under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0). You may copy and redistribute the material for noncommercial purposes, provided that appropriate credit is given and a link to the license is included. Modified versions may not be distributed under this license.
License: https://creativecommons.org/licenses/by-nc-nd/4.0/
References
Mamun SMAA, Jahan R, Islam QT, et al. Rational of using common antifibrotic therapy in post COVID fibrosis. J Med 2021;22(1):46-50. ID: covidwho-1059839
Chung MP, Park MS, Oh IJ, et al. Safety and efficacy of perfenidine in advanced idiopathic pulmonary fibrosis. Adv Ther 2020;37(5);2303-16. doi: 10.1007/s12325-020-01328-8.
Thille AW, Estaban A, Fernandez-Segoviano P, et al. Chronology of histological lesions in acute respiratory distress syndrome with diffuse alveolar damage: A prospective cohort study of clinical autopsies. Lancet Respir Med 2013;1(5):395-401. doi: 10.1016/S2213-2600(13)70053-5.
Umemaru Y, Mitsuyama Y, Minami K, et al. Efficacy and safety of nintedanib for pulmonary fibrosis in severe pneumonia induced by COVID-19: An interventional study. Int J Infect Dis 2021;108:454-60. doi: 10.1016/j.ijid.2021.05.055.
Ogata H, Nakagawa T, Sakoda S, et al. Nintedanib treatment for pulmonary fibrosis aftercoronavirus 2019. Respirol Case Rep 2021;9(5):e00744. doi: 10.1002/rcr2.744.
Vitug LC, Santiaguel J. Nintedanib as in adjunct treatment in improving lung function of post-COVID-19 pulmonary fibrosis in an elderly patient: a case report. Chest 2021:160(4):A2166. doi: 10.1016/j.chest.2021.07.1914
Singh P, Behera D, Gupta S, et al. Nintedanib vs perfenidone in the management of COVID-19 lung fibrosis: A single center study. JRCPE 2022:1-6. doi: 10.1177/14782715221103402
